AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27839596 — intervention group
Group type: EXPERIMENTAL
Intervention: Blurred lens with target laser turned off
Number of subjects: 11
Study 27839596 — intervention group
Group type: EXPERIMENTAL
Intervention: +3.0 D lens with target laser on
Number of subjects: 11
Study 27839596 — intervention group
Group type: EXPERIMENTAL
Intervention: +3.0 D lens with target laser turned off
Number of subjects: 11
Study 27536454 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranlukast
Number of subjects: 30
Study 27536454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 22580856 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CyA)
Number of subjects: 53
Study 22580856 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus (Tac)
Number of subjects: 53
Study 20048227 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 205
Study 20048227 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy guided self-help (CBTgsh)
Number of subjects: 205
Study 20048227 — intervention group
Group type: COMPARATOR
Intervention: Behavioral weight loss treatment (BWL)
Number of subjects: 205
Study 17875007 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alpha‐2a plus ribavirin
Number of subjects: 380
Study 17875007 — intervention group
Group type: COMPARATOR
Intervention: peginterferon alpha‐2b plus ribavirin
Number of subjects: 380
Study 16156881 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir 100 mg twice-daily added to nelfinavir 1250 mg twice-daily regimen
Number of subjects: 16
Study 16156881 — intervention group
Group type: COMPARATOR
Intervention: Nelfinavir 1250 mg twice-daily regimen without ritonavir
Number of subjects: 16
Study 12360161 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 2588
Study 8017414 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin through PVC administration set
Number of subjects: 140
Study 8017414 — intervention group
Group type: COMPARATOR
Intervention: Intravenous nitroglycerin through polyethylene administration set
Number of subjects: 140
Study 3174725 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid 'Diasorb' (smectite)
Number of subjects: 80
Study 3174725 — intervention group
Group type: COMPARATOR
Intervention: Loperamide
Number of subjects: 80
Study 31169407 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane anaesthesia
Number of subjects: 20
Study 31169407 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia (TIVA) with Propofol
Number of subjects: 20
Study 28771503 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrowband UVB treatment
Number of subjects: 1749
Study 26084281 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance exercise program, performed twice a week for 15 weeks
Number of subjects: 130
Study 26084281 — intervention group
Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 130
Study 23550694 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-hypnosis group (three 1-h lessons in self-hypnosis with audio-recordings)
Number of subjects: 1222
Study 23550694 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation group (three 1-h lessons in relaxation methods and mindfulness with audio-recordings)
Number of subjects: 1222
Study 23550694 — intervention group
Group type: COMPARATOR
Intervention: Usual-care group (only usual antenatal care)
Number of subjects: 1222
Study 23550694 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-hypnosis group
Number of subjects: 1222
Study 23550694 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation group
Number of subjects: 1222
Study 23550694 — intervention group
Group type: COMPARATOR
Intervention: Usual-care group
Number of subjects: 1222
Study 21804375 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole/amoxicillin/levofloxacin (EAL) - 40 mg esomeprazole twice daily, 1 g amoxicillin twice daily and 500 mg levofloxacin once daily for 7 days
Number of subjects: 90
Study 21804375 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole/amoxicillin/metronidazole (EAM) - 40 mg esomeprazole twice daily, 1 g amoxicillin twice daily and 250 mg metronidazole 4 times daily for 14 days
Number of subjects: 90
Study 19142961 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative mouse
Number of subjects: 206
Study 19142961 — intervention group
Group type: EXPERIMENTAL
Intervention: Forearm support board
Number of subjects: 206
Study 19142961 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention mentioned)
Number of subjects: 206
Study 17042884 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine monotherapy (up to 800 mg/day)
Number of subjects: 1006
Study 17042884 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine + Lithium/Divalproex (up to 800 mg/day)
Number of subjects: 1006
Study 17042884 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol monotherapy
Number of subjects: 1006
Study 17042884 — intervention group
Group type: COMPARATOR
Intervention: Lithium monotherapy
Number of subjects: 1006
Study 17042884 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine monotherapy
Number of subjects: 1006
Study 17042884 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine + Lithium/Divalproex
Number of subjects: 1006
Study 17042884 — intervention group
Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 1006
Study 17042884 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 1006
Study 14742097 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine (50 mg)
Number of subjects: 19
Study 14742097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 11315997 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractal analysis of trabecular bone texture (H parameter)
Number of subjects: 304
Study 11315997 — intervention group
Group type: EXPERIMENTAL
Intervention: Low H values combined with BMD measurements
Number of subjects: 304
Study 9596457 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan nasal spray 20 mg
Number of subjects: 1086
Study 9596457 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan nasal spray 10 mg
Number of subjects: 1086
Study 9596457 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan nasal spray 5 mg
Number of subjects: 1086
Study 9596457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1086
Study 9596457 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan nasal spray
Number of subjects: 1086
Study 7696164 — intervention group
Group type: EXPERIMENTAL
Intervention: AVP induction chemotherapy (adriamycin, etoposide, cisplatin given every four weeks for four cycles)
Number of subjects: 266
Study 7696164 — intervention group
Group type: EXPERIMENTAL
Intervention: EVA induction chemotherapy (cyclophosphamide, etoposide, adriamycin given every four weeks for four cycles)
Number of subjects: 266
Study 7696164 — intervention group
Group type: EXPERIMENTAL
Intervention: MOC/AVP induction chemotherapy (methotrexate, vincristine, cyclophosphamide alternating with adriamycin, etoposide, cisplatin for two cycles)
Number of subjects: 266
Study 7696164 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined-modality maintenance therapy (radiation therapy to the chest followed by MOC/EVA chemotherapy)
Number of subjects: 266
Study 7696164 — intervention group
Group type: COMPARATOR
Intervention: Maintenance chemotherapy alone (without consolidating chest irradiation)
Number of subjects: 266
Study 2622586 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritodrine and potassium chloride
Number of subjects: 42
Study 2622586 — intervention group
Group type: EXPERIMENTAL
Intervention: Carnitine (2 g infusion with phleboclysis)
Number of subjects: 42
Study 2622586 — intervention group
Group type: COMPARATOR
Intervention: Tocolytics per os (oral)
Number of subjects: 42
Study 981 — intervention group
Group type: EXPERIMENTAL
Intervention: 11.2% mafenide acetate cream
Number of subjects: 37
Study 981 — intervention group
Group type: COMPARATOR
Intervention: 5% mafenide acetate cream
Number of subjects: 37
Study 981 — intervention group
Group type: COMPARATOR
Intervention: Carrier cream without glycerol
Number of subjects: 37
Study 30782522 — intervention group
Group type: EXPERIMENTAL
Intervention: Approach-Bias Modification (AppBM) training
Number of subjects: 149
Study 30782522 — intervention group
Group type: COMPARATOR
Intervention: Sham training
Number of subjects: 149
Study 30782522 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 149
Study 28699390 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic inspired Valsalva (group A)
Number of subjects: 48
Study 28699390 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic expired Valsalva (group B)
Number of subjects: 48
Study 28699390 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon-inspired Valsalva (group C)
Number of subjects: 48
Study 28699390 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon-expired Valsalva (group D)
Number of subjects: 48
Study 28699390 — intervention group
Group type: COMPARATOR
Intervention: Combined classic Valsalva (groups A and B)
Number of subjects: 48
Study 28699390 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 48
Study 25867274 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen followed by anastrozole
Number of subjects: 1324
Study 25867274 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) after breast conservation therapy (BCT)
Number of subjects: 1324
Study 25867274 — intervention group
Group type: COMPARATOR
Intervention: Breast conservation surgery (BCT) and mastectomy (MX)
Number of subjects: 1324
Study 23786655 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin (VP) 0.01 to 0.03 U/min
Number of subjects: 121
Study 23786655 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine (NE) 5 to 15 μg/min
Number of subjects: 121
Study 23786655 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin (VP)
Number of subjects: 121
Study 23786655 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine (NE)
Number of subjects: 121
Study 22042725 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise programmes
Number of subjects: 270
Study 22042725 — intervention group
Group type: EXPERIMENTAL
Intervention: Native English speakers
Number of subjects: 270
Study 19287305 — intervention group
Group type: EXPERIMENTAL
Intervention: multiple hepatic arterial injections of Ad‐p53 (1x10 viral particles) and 5‐FU (500‐750 mg), after TACE
Number of subjects: 46
Study 19287305 — intervention group
Group type: COMPARATOR
Intervention: TACE alone
Number of subjects: 46
Study 17885005 — intervention group
Group type: EXPERIMENTAL
Intervention: Soymilk (28.51 mg isoflavone aglycone equivalents/portion)
Number of subjects: 100
Study 17885005 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy germ (37.99 mg isoflavone aglycone equivalents/portion)
Number of subjects: 100
Study 17885005 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong equol producer phenotype
Number of subjects: 100
Study 17885005 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher PUFA intake
Number of subjects: 100
Study 17885005 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher alcohol intake
Number of subjects: 100
Study 15166881 — intervention group
Group type: EXPERIMENTAL
Intervention: Thallium-201 SPECT with attenuation correction (ATC)
Number of subjects: 39
Study 15166881 — intervention group
Group type: COMPARATOR
Intervention: Thallium-201 SPECT without attenuation correction (non-ATC)
Number of subjects: 39
Study 12445377 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant CPT-11 after cryosurgery
Number of subjects: 153
Study 12445377 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic FUDR after cryosurgery
Number of subjects: 153
Study 12445377 — intervention group
Group type: COMPARATOR
Intervention: Cryosurgery alone
Number of subjects: 153
Study 12445377 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival from diagnosis of liver metastases
Number of subjects: 153
Study 12445377 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival from time of CSA
Number of subjects: 153
Study 12445377 — intervention group
Group type: EXPERIMENTAL
Intervention: Second CSA
Number of subjects: 153
Study 9704757 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic hysterectomy
Number of subjects: 44
Study 9704757 — intervention group
Group type: COMPARATOR
Intervention: Abdominal hysterectomy
Number of subjects: 44
Study 8034812 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (16 sessions)
Number of subjects: 47
Study 8034812 — intervention group
Group type: COMPARATOR
Intervention: Wait-list condition
Number of subjects: 47
Study 2564458 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term interferon therapy
Number of subjects: 31
Study 2564458 — intervention group
Group type: COMPARATOR
Intervention: Withdrawal of interferon
Number of subjects: 31
Study 2564458 — intervention group
Group type: EXPERIMENTAL
Intervention: Resumption of interferon therapy
Number of subjects: 31
Study 30426268 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebamipide 2%
Number of subjects: 0
Study 30426268 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebamipide 4%
Number of subjects: 0
Study 30426268 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28571727 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentha pulegium extract (330mg three times daily for 2 months)
Number of subjects: 50
Study 28571727 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentha pulegium extract
Number of subjects: 50
Study 28571727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 26194565 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended sleep (EXT, 9.8 ± 0.1 h time in bed)
Number of subjects: 14
Study 26194565 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended sleep (EXT)
Number of subjects: 14
Study 26194565 — intervention group
Group type: COMPARATOR
Intervention: Habitual sleep (HAB, 8.2 ± 0.1 h time in bed)
Number of subjects: 14
Study 22959603 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO‐SELF Plus Pain Control Program (6 visits and 4 phone calls over 10 weeks)
Number of subjects: 39
Study 22959603 — intervention group
Group type: COMPARATOR
Intervention: Standard education and care (control group)
Number of subjects: 39
Study 22303583 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg kg‐1 nettle extract, three portions a day for 8 weeks
Number of subjects: 50
Study 22303583 — intervention group
Group type: COMPARATOR
Intervention: Placebo, three portions a day for 8 weeks
Number of subjects: 50
Study 19190859 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-Eluting Stent (SES)
Number of subjects: 2769
Study 19190859 — intervention group
Group type: COMPARATOR
Intervention: Bare Metal Stent (BMS)
Number of subjects: 2769
Study 16409198 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (latex immunotherapy)
Number of subjects: 24
Study 16409198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 12654431 — intervention group
Group type: COMPARATOR
Intervention: Conventional RT
Number of subjects: 926
Study 12654431 — intervention group
Group type: COMPARATOR
Intervention: Conventional RT and adjuvant chemotherapy
Number of subjects: 926
Study 12654431 — intervention group
Group type: COMPARATOR
Intervention: Conventional RT plus concurrent chemotherapy
Number of subjects: 926
Study 12654431 — intervention group
Group type: COMPARATOR
Intervention: Conventional RT plus concurrent chemotherapy and adjuvant chemotherapy
Number of subjects: 926
Study 11140556 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive systemic doxycycline (200 mg the 1st day, then 100 mg per day for 21 days)
Number of subjects: 39
Study 11140556 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing
Number of subjects: 39
Study 9127062 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom-as-clinic format (n = 45)
Number of subjects: 127
Study 9127062 — intervention group
Group type: COMPARATOR
Intervention: Non-classroom-as-clinic format (n = 82)
Number of subjects: 127
Study 1441695 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimobendan 5 mg bid
Number of subjects: 24
Study 1441695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 3548207 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam 40 mg/day for two days followed by 20 mg/day
Number of subjects: 91
Study 3548207 — intervention group
Group type: COMPARATOR
Intervention: Mefenamic acid 500 mg t.i.d.
Number of subjects: 91
Study 3548207 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 50 mg b.i.d.
Number of subjects: 91
Study 30486723 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial Extracorporeal Shock Wave Therapy (rESWT) - 3,000 pulses each; pressure: 1.8‐2.0 bar; frequency: 10 Hz, once a week for 8 weeks.
Number of subjects: 45
Study 30486723 — intervention group
Group type: COMPARATOR
Intervention: Combination of an α‐blocker and an anti‐inflammatory agent, treated for 8 weeks.
Number of subjects: 45
Study 29350481 — intervention group
Group type: EXPERIMENTAL
Intervention: Reassurance
Number of subjects: 73
Study 29350481 — intervention group
Group type: COMPARATOR
Intervention: Distraction
Number of subjects: 73
Study 29350481 — intervention group
Group type: COMPARATOR
Intervention: Reappraisal
Number of subjects: 73
Study 26840637 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine weighing at each antenatal visit with counselling according to IOM guidelines
Number of subjects: 782
Study 26840637 — intervention group
Group type: COMPARATOR
Intervention: Standard antenatal care (recording weight at booking and then at 36 weeks)
Number of subjects: 782
Study 24762108 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-448 (0.01-6 mg/d; single-bolus or 2-hour infusion)
Number of subjects: 112
Study 24762108 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-448 (0.01-1 mg/d; 14-day sc administration)
Number of subjects: 112
Study 24762108 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-448 (12 or 24 mg sc-depot injections)
Number of subjects: 112
Study 24762108 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-448 (24 mg sc-depot injections)
Number of subjects: 112
Study 24762108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 22549752 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesorectal-LN group
Number of subjects: 11567
Study 22549752 — intervention group
Group type: COMPARATOR
Intervention: Internal-LPLN group
Number of subjects: 11567
Study 22549752 — intervention group
Group type: COMPARATOR
Intervention: N2b group
Number of subjects: 11567
Study 22549752 — intervention group
Group type: EXPERIMENTAL
Intervention: External-LPLN group
Number of subjects: 11567
Study 20548010 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (11 individual and 11 group counseling sessions with a dietitian, 22 physical activity group sessions per year)
Number of subjects: 201
Study 20548010 — intervention group
Group type: COMPARATOR
Intervention: Moderate lifestyle intervention (3 individual and 2 group dietary counseling sessions per year, no guided physical activity)
Number of subjects: 201
Study 20548010 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 201
Study 20548010 — intervention group
Group type: COMPARATOR
Intervention: Moderate lifestyle intervention
Number of subjects: 201
Study 17208597 — intervention group
Group type: EXPERIMENTAL
Intervention: 650 mg aspirin twice daily
Number of subjects: 137
Study 17208597 — intervention group
Group type: EXPERIMENTAL
Intervention: 325 mg aspirin twice daily
Number of subjects: 137
Study 14991499 — intervention group
Group type: EXPERIMENTAL
Intervention: Diathermy excision hemorrhoidectomy (Group A, n = 25)
Number of subjects: 45
Study 14991499 — intervention group
Group type: COMPARATOR
Intervention: Diathermy coagulation (Group B, n = 20)
Number of subjects: 45
Study 12471296 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume rope jumping (10 min)
Number of subjects: 37
Study 12471296 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume rope jumping (5 min)
Number of subjects: 37
Study 12471296 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 37
Study 9803800 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolysis
Number of subjects: 0
Study 9803800 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0
Study 9803800 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine kinase
Number of subjects: 0
Study 9803800 — intervention group
Group type: EXPERIMENTAL
Intervention: MB isoform
Number of subjects: 0
Study 8582195 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen replacement therapy
Number of subjects: 0
Study 8582195 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined or opposed hormone replacement therapy (HRT)
Number of subjects: 0
Study 8582195 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 0
Study 8582195 — intervention group
Group type: EXPERIMENTAL
Intervention: Feasibility studies
Number of subjects: 0
Study 1978546 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 0
Study 1978546 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 0
Study 686354 — intervention group
Group type: EXPERIMENTAL
Intervention: Carticaine 1%
Number of subjects: 14
Study 686354 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine 1%
Number of subjects: 14
Study 31831270 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 50
Study 31831270 — intervention group
Group type: COMPARATOR
Intervention: Sham (touching points within 1 cm of main points)
Number of subjects: 50
Study 31169862 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept (2.0 mg)
Number of subjects: 346
Study 31169862 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (1.25 mg)
Number of subjects: 346
Study 28346568 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-monthly oral doses of 3 mg calcifediol plus daily exercise
Number of subjects: 675
Study 28346568 — intervention group
Group type: COMPARATOR
Intervention: Placebo with standard health recommendations
Number of subjects: 675
Study 25996764 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (ITM)
Number of subjects: 32